StocksMedium•5 November 2026•
1 min read
Aspen Aerogels and Agios Pharmaceuticals Post Strong Q3 Revenue Growth
Key Facts
1Aspen Aerogels reported Q3 revenue of $85 million, up 71% quarter-over-quarter and exceeding its outlook.
2Agios Pharmaceuticals delivered $55.4 million in net revenues from Mitapivat, more than four times the prior year's Q3.
3The FDA set a new PDUFA goal date of February 1, 2027, for Agios' mitapivat sickle cell disease sNDA.
Aspen Aerogels reported Q3 2026 revenue of $85 million, marking a 71% increase over the previous quarter and exceeding its own outlook, according to GlobeNewswire. Simultaneously, Agios Pharmaceuticals delivered $55.4 million in net revenues from its drug Mitapivat, representing more than four times the revenue generated in the same period last year.
Aspen Aerogels (ASPN) closed at $4.80 on November 4, 2026, while Agios Pharmaceuticals (AGIO) closed at $31.38 on the same date. Aspen's growth was driven by record EU OEM revenue and new data center infrastructure orders, while Agios received a new FDA PDUFA goal date of February 1, 2027, for its sickle cell disease treatment application.